Source: Annual Congress 2013 –COPD treatment and others
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Basina, T. Pertseva, L. Konopkina (Dnipropetrovsk, Ukraine). Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level. Eur Respir J 2013; 42: Suppl. 57, 3666

Member's Comments

No comment yet.

Related content which might interest you: Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients? Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers Source: International Congress 2016 – Systemic biomarkers Year: 2016 Stable state MR-proadrenomedullin level in COPD patients; a validation study Source: International Congress 2014 – Comorbidities Year: 2014 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Concentration of C-reactive protein (CRP) in elderly asthmatics Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015 Serum sirtuin-1 is reduced in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Inflammatory markers (IL-6, suPAR) and arterial stiffness parameters in COPD patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Association of angiopoietin-like protein 4 with cardiovascular function in patients with COPD Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD Source: International Congress 2014 – Predictors Year: 2014 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Evaluation of procalcitonin (PCT) and neopterin levels in acute exacerbations of COPD Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005 Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013